Search

Engineering skeletal muscle tissue is crucial for the repair and replacement of damaged or dysfunctional muscle. Despite numerous studies emphasizing the significance of skeletal muscle engineering, challenges persist in effectively replacing or repairing large muscle sections in vivo. Bioreactors that facilitate the rapid expansion of muscle precursor cells present a promising solution for addressing extensive muscle loss. Specifically, bioreactors that mimic the native microenvironment of muscle tissue can induce biomimetic stimuli, selectively promoting the expansion of muscle precursors with optimal myo‐regenerative potential. In this review, the advancements made in utilizing bioreactors to enhance the myo‐regenerative phenotype of cells for skeletal muscle engineering are highlighted. [ABSTRACT FROM AUTHOR]

Studying the behavior of electroactive cells, such as firing dynamics and chemical secretion, is crucial for developing human disease models and therapeutics. Following the recent advances in cell culture technology, traditional monolayers are optimized to resemble more 3D, organ‐like structures. The biological and electrochemical complexity of these structures requires devices with adaptive shapes and novel features, such as precise electrophysiological mapping and stimulation in the case of brain‐ and heart‐derived tissues. However, conventional organ‐on‐chip platforms often fall short, as they do not recreate the native environment of the cells and lack the functional interfaces necessary for long‐term monitoring. Origami‐on‐a‐chip platforms offer a solution for this problem, as they can flexibly adapt to the structure of the desired biological sample and can be integrated with functional components enabled by chosen materials. In this review, the evolution of origami‐on‐a‐chip biointerfaces is discussed, emphasizing folding stimuli, materials, and critical findings. In the prospects, microfluidic integration, functional tissue engineering scaffolds, and multi‐organoid networks are included, allowing patient‐specific diagnoses and therapies through computational and in vitro disease modeling. [ABSTRACT FROM AUTHOR]

Engineering skeletal muscle tissue is crucial for the repair and replacement of damaged or dysfunctional muscle. Despite numerous studies emphasizing the significance of skeletal muscle engineering, challenges persist in effectively replacing or repairing large muscle sections in vivo. Bioreactors that facilitate the rapid expansion of muscle precursor cells present a promising solution for addressing extensive muscle loss. Specifically, bioreactors that mimic the native microenvironment of muscle tissue can induce biomimetic stimuli, selectively promoting the expansion of muscle precursors with optimal myo‐regenerative potential. In this review, the advancements made in utilizing bioreactors to enhance the myo‐regenerative phenotype of cells for skeletal muscle engineering are highlighted.

Studying the behavior of electroactive cells, such as firing dynamics and chemical secretion, is crucial for developing human disease models and therapeutics. Following the recent advances in cell culture technology, traditional monolayers are optimized to resemble more 3D, organ‐like structures. The biological and electrochemical complexity of these structures requires devices with adaptive shapes and novel features, such as precise electrophysiological mapping and stimulation in the case of brain‐ and heart‐derived tissues. However, conventional organ‐on‐chip platforms often fall short, as they do not recreate the native environment of the cells and lack the functional interfaces necessary for long‐term monitoring. Origami‐on‐a‐chip platforms offer a solution for this problem, as they can flexibly adapt to the structure of the desired biological sample and can be integrated with functional components enabled by chosen materials. In this review, the evolution of origami‐on‐a‐chip biointerfaces is discussed, emphasizing folding stimuli, materials, and critical findings. In the prospects, microfluidic integration, functional tissue engineering scaffolds, and multi‐organoid networks are included, allowing patient‐specific diagnoses and therapies through computational and in vitro disease modeling.